We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Global Digital Pathology Market Worth USD 1,052 Million by 2022

By LabMedica International staff writers
Posted on 25 Jul 2016
Print article
The global digital pathology market will reach USD 1,052 million by 2022, driven by the growing popularity of virtual slides over physical slides, technological advancements, and cost-effective products, with North America accounting for the major share.

According to a new Allied Market Research (Portland OR, USA) report, other factors such as workflow efficiency, analysis efficiency, improved productivity and patient care, and accuracy are also contributing to the market growth. However, lack of reimbursement policies, inadequate infrastructure, and pending product approvals are restraining the growth of the global digital pathology market.

Digitalization of pathology, where glass slides are converted into digital images for easy viewing, analysis, storage, and management of collected data, has resulted in automation of tests during diagnosis, thus saving cost and efforts. For instance, pathologists can now perform tests using a single digital instrument instead of five instruments required earlier.

Based on product, the market is segmented into whole slide imaging (WSI), image analysis informatics, information management system storage & communication, and others. WSI is the major segment and is expected to grow at a CAGR of 14.8% from 2014 to 2022, due to its diversified use in surgical pathology, clinical diagnosis, consultation, and education, as well as in proficiency testing, which is a part of cytopathology.

Within the WSI segment, the scanners/digitizers segment accounted for the largest share in 2015, while reagents is projected to be the fastest growing segment at a CAGR of 15.3% from 2014 to 2022. The image analysis-informatics segment is the fastest growing segment, growing at a CAGR of 25.2%, and along with the WSI segment, it comprises about three-fourths of the total market.

Based on end user, the market is segmented into educational institutes, hospitals and diagnostic centers; and pharmaceutical & biotechnology companies. In 2015, hospitals and diagnostic centers and pharmaceutical & biotechnology end user segments together accounted for a share of more than 70% of the market. Pharmaceutical & biotechnology companies are projected to be the fastest growing end use segment, growing at a CAGR of 19.9% from 2014 to 2022.

In terms of geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In 2015, Asia Pacific and LAMEA together accounted for about 20% of the market. The German digital pathology market is expected to reach about USD50 million by 2022, growing at a CAGR of 14.5% over the period 2014 to 2022.

In 2015, North America accounted for the major share of the overall digital pathology market and is expected to grow at a CAGR of 14.7% from 2014 to 2022, driven mainly by a large number of hospitals and clinics adopting digital pathology procedures for accurate results and improved efficiency. In North America, WSI is expected to dominate the market followed by image analysis-informatics. However, Asia-Pacific is expected to grow rapidly at a CAGR of 26.6%, with the major contribution to come from China due to its cost-effective products and image analysis-informatics to be the fastest growing segment in the region with a CAGR of 34.9%.

Currently, companies are adopting collaborations, product launches, and agreements as their key development strategies in the market. An increase in the number of initiatives for commercializing cost-efficient digital pathology systems is expected to offer profitable growth opportunities for service providers in the future.

The key companies in the global digital pathology market are Definiens AG (Munich, Germany), Visiopharm (Hørsholm, Denmark), Indica Labs (Corrales, NM, USA), Digipath, Wichita, KS, USA), Danaher Corporation (Leica Microsystem) (Washington, D.C., USA), Koninklinje Philips N.V. (Amsterdam, Netherlands), Hamamatsu Photonics K. K. (Hamamatsu, Japan), PerkinElmer, Inc. (Waltham, MA; USA), Nikon Corporation (Tokyo, Japan), Pixcelldata Ltd. (Dublin 2, Ireland), and Glencoe Software Inc. (Seattle, WA, USA).

Related Links:
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Thyroxine ELISA
T4 ELISA
New
Rocking Shaker
HumaRock

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.